87 First-in-Human Study of [111In] XYIMSR-01 SPECT/CT, a Novel Carbonic Anhydrase IX Small Molecule in Patients with Metastatic Clear Cell Renal Cell Carcinoma

Yasser Ged · 2026

Read 87 First-in-Human Study of [111In] XYIMSR-01 SPECT/CT, a Novel Carbonic Anhydrase IX Small Molecule in Patients with Metastatic Clear Cell Renal Cell Carcinoma by Yasser Ged (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13535428.txt.

Description

Yasser Ged leads a first-in-human imaging trial in spread kidney cancer in a 2026 study. Clear cell kidney tumors almost always overproduce a surface enzyme, CAIX, after losing a key tumor suppressor. A small molecule that homes to that enzyme could light the tumors up on scans and later carry therapy.

The tracer XYIMSR-01, tagged with radioactive indium-111, was designed to clear fast and give same-day pictures with high contrast. Animal studies showed strong, selective tumor uptake. The phase I trial at one center now tests safety and scanning feasibility in untreated patients with at least two sizable metastases.

Catalog record

CREATORYasser Ged
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13535428

Browse the full library · About the Tower of Babel